Fierce Pharma

JUNE 24, 2024

In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events in patient | In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events.

Pharmaceutical 319

Pharmaceutical Patients 319

MedCity News

JUNE 24, 2024

Multiple stakeholders are to blame for prescription drug costs, including pharmaceutical companies and PBMs, according to Merith Basey, executive director of Patients for Affordable Drugs. The post Who Is Responsible for the High Cost of Prescription Drugs? One Advocate Weighs In appeared first on MedCity News.

Prescription 137

Prescription Pharmaceutical Patients Pharma 137

Fierce Pharma

JUNE 24, 2024

After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. | After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. And what better way to do it than to win a major contract in your rival’s home country? The U.K. government has selected Pfizer to supply 5 million doses of its RSV shot Abrysvo over the next two years.

Government 317

Government 317

MedCity News

JUNE 24, 2024

Argenx’s Vyvgart Hytrulo is now approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare autoimmune disease that affects nerves and impairs muscle function. The drug, an FcRn inhibitor, is the first in its class to win FDA approval in CIDP. The post FDA Approves Argenx Drug as First New Treatment in Decades for Rare Nerve Disease CIDP appeared first on MedCity News.

FDA 128

FDA Biopharma Pharma 128

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

JUNE 24, 2024

Following Novo Nordisk’s recent Wegovy approval to cut heart risks in adults with obesity, Eli Lilly appears to be homing in on the next potential label expansion for its rival GIP/GLP-1 weigh | Late last week, Lilly shared detailed results from its phase 3 SURMOUNT-OSA study, which found that Zepbound at the 10 mg and 15 mg doses aced its primary and secondary endpoints in obese patients with obstructive sleep apnea (OSA).

FDA 299

FDA Patients 299

MedCity News

JUNE 24, 2024

There is an urgent need for health systems to develop efficient strategies that balance improved patient outcomes with financial health — here are three areas to focus on. The post Unraveling Healthcare Innovation Spend: Where Healthtech Founders Need to Focus appeared first on MedCity News.

Healthcare 118

Healthcare Healthcare Patients 118

MedCity News

JUNE 24, 2024

Healthcare organizations must ensure that every solution incorporated into the connected ecosystem is designed and tested to validate that it is secure, compliant, and performs as expected. The post Connected Healthcare: Solving the Challenges with Medical Devices appeared first on MedCity News.

Healthcare 115

Healthcare Healthcare Medical 115

Fierce Pharma

JUNE 24, 2024

Despite coming to market second, Bristol Myers Squibb’s Mirati Therapeutics-inherited cancer med Krazati has gained the lead on its Amgen rival Lumakras in a heated KRAS race. | Late Friday, the U.S. FDA granted an accelerated approval for BMS’ KRAS inhibitor Krazati plus Eli Lilly’s Erbitux (cetuximab) to treat certain chemotherapy-experienced adults with KRAS-mutated locally advanced or metastatic colorectal cancer.

Leads 240

Leads FDA Marketing 240

pharmaphorum

JUNE 24, 2024

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer

FDA 111

FDA 111

Fierce Pharma

JUNE 24, 2024

Following last week’s news that generic drugmaker Hikma is acquiring parts of Xellia’s assets in the U.S., the Danish drugmaker has unveiled plans for a fresh round of layoffs. | In connection with the sale of the company’s Bedford plant on the outskirts of Cleveland, Ohio, to Hikma, Xellia said it’s cutting 247 positions in the U.S. Of the affected staffers, 214 work at the Bedford facility, Xellia said in a Worker Adjustment and Retraining Notification alert sent to the state.

Sales 203

Sales 203

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

pharmaphorum

JUNE 24, 2024

Fenofibrate, a decades-old drug used to lower cholesterol levels, has been shown to reduce the progression of diabetic retinopathy in a large-scale trial.

111

111

Fierce Pharma

JUNE 24, 2024

Over the years, ANI Pharmaceuticals has grown itself in part through a series of strategic acquisitions. | Over the years, ANI Pharmaceuticals has grown itself in part through a series of strategic acquisitions. Now, the company has inked a sizable deal to get its hands on ophthalmology specialist Alimera Sciences and its two approved commercial drugs.

Pharmaceutical 184

Pharmaceutical 184

pharmaphorum

JUNE 24, 2024

Alnylam shares spike after vutrisiran aces HELIOS-B trial in ATTR-cardiomyopathy, setting up regulatory filings

111

111

MedCity News

JUNE 24, 2024

Novant Health called off its planned $320 million acquisition of two CHS-owned hospitals in North Carolina. The decision came after an appellate court granted the FTC an emergency injunction to block the deal — the agency had been challenging the deal for more than a year. The post FTC Involvement Forces Novant Health to Scrap Its $320M Deal with CHS appeared first on MedCity News.

110

110

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

JUNE 24, 2024

Novo Nordisk boosts manufacturing capacity for GLP-1 drugs again, unveiling a $4.

Manufacturing 109

Manufacturing 109

PharmaVoice

JUNE 24, 2024

With a career focused on striking deals, Kaan Cartel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.

Leads 106

Leads 106

Pharmaceutical Technology

JUNE 24, 2024

The osteoporosis market is expected to grow at a compound annual growth rate of 5.4% from 2023 to 2032, reaching $17.9bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) by the end of this forecast period, according to leading data and analytics company GlobalData’s recent report: Osteoporosis: Seven-Market Drug Forecast and Market Analysis.

Marketing 105

Marketing Leads 105

Pharmaceutical Commerce

JUNE 24, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

Advertisement

pharmaphorum

JUNE 24, 2024

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).Ezharmia (valemetostat tosylate) remains the first and only drug in the class to be approved for marketing around the world, having been cleared in Japan in 2022 for relapsed or refractory adult T-cell leukaemia/lymphoma (ATL).

Marketing 105

Marketing 105

Pharmaceutical Commerce

JUNE 24, 2024

A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.

105

105

Pharmaceutical Technology

JUNE 24, 2024

Big pharma and their packaging partners are collaborating to cut emissions and deliver more sustainable solutions for injectables.

Pharma 97

Pharma 97

PharmaTimes

JUNE 24, 2024

The manifesto calls on the next UK government to make dementia a key health priority

Government 94

Government 94

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

European Pharmaceutical Review

JUNE 24, 2024

SGS customers now have easier access to biopharmaceutical insights as the Birsfelden, Switzerland lab adds a stability studies service. The lab now offers reliable, cost-efficient stability testing, including sample storage and related analytical services under controlled conditions, adhering to ICH Q5C guidelines. SGS project managers oversee studies.

Management 69

Management Pharmaceutical 69

PharmaTimes

JUNE 24, 2024

The initiative aims to improve African pandemics, outbreaks, preparedness and responses

Manufacturing 86

Manufacturing 86

Integrity Solutions

JUNE 24, 2024

Imagine having a sales team coach who sees the potential in you that you don’t even see in yourself—and then is committed to helping you help live up to that potential. Most leaders agree that the role of sales team coach play a key role in helping salespeople achieve their goals. However, there’s a big gap between this recognition of the importance of coaching and the amount of coaching that’s actually being done.

Sales 65

Sales Sales Management Management Sales tools 65

PM360

JUNE 24, 2024

Over the past 20 years FUEL has transformed into a highly anticipated, multi-day event with immeasurable value for the EVERSANA INTOUCH team and clients alike. EVERSANA INTOUCH has always had a focus on innovation and new ways of thinking, dating back to the agency’s founding, when Faruk Capan some 25 years ago envisioned a better marketing agency to service the pharmaceutical industry.

Consulting 64

Consulting Marketing Networking Pharma 64

Advertisement

Distribution

PharmaTech

JUNE 24, 2024

A new initiative will advance access to quality medicines and vaccines in Africa.

Pharma 64

Pharma Medicine 64

PM360

JUNE 24, 2024

In the rapidly evolving global healthcare landscape, the relationship between patients and healthcare professionals (HCPs) remains crucial for effective treatment and care delivery. However, maintaining meaningful interactions between patients and physicians has become increasingly challenging amid the complexities of clinical data management and modern medical practice demands, impacting patient satisfaction, trust, and healthcare outcomes.

Physicians 59

Physicians Patients Healthcare Provider Healthcare 59

Pharmaceutical Technology

JUNE 24, 2024

Alimera Sciences shares have increased following a $5.50 per share buyout offer from ANI Pharmaceuticals.

Pharmaceutical 59

Pharmaceutical 59

PM360

JUNE 24, 2024

AI-powered chatbots are trying to fill a gap in human mental health providers. PATIENT PAGES How Patients Feel About AI-Powered Therapy Although Americans may be more willing to seek mental health care, there is a shortage of mental health care providers and lack of access for many patients. Telehealth has broadened access, but it may still not be enough.

Media 59

Media Physicians FDA Pharma 59

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales